John, c- can you add on to, uh, what, what Bethany just said?

I can.

I, I thought it was really well said, Bethany, and I, I would point out that where- whereas Bethany covered the FDA decisions, like once a product gets to market, the, the pricing is gonna play out in the context of whatever the market rules are, um, and the population and payer, uh, norms and rules are, um, for that specific drug.

So to give examples of that, you know, choosing between a small molecule versus a biologic drug.

Well, now in the Medicare program, if it's a, a high revenue drug, you now have potential Inflation Reduction Act Medicare negotiation programs that differ depending on whether it's a small molecule or a biologic.

Um, the route of administration might determine if it's a Medicare Part B versus a Medicare Part D drug.

Uh, with Part B, you're gonna be dealing with, you know, one way in which you get reimbursed for that product.

How do you navigate? How do, how do you advise your clients to navigate in this environment?